Back to News & Events

Next HHS SBIR/STTR Application Deadline 9/6 – Get Started Today

September 6 is the next HHS SBIR/STTR standard deadline. Talk to an HHS SBIR/STTR program manager today for advice: http://bit.ly/SBIR_IC_Contacts

The next HHS SBIR/STTR application deadline is less than two months away on Tuesday, September 6, 2016 at 5 pm local time. (Note – the standard deadline falls on September 5, a federal holiday, so the revised deadline is September 6).

Make sure you are registered! The 5-step registration process may take 6 – 8 weeks, so it is important to start now. All registrations must be completed prior to the application being submitted, and the System for Awards Management (SAM) registration must be updated annually. Learn more about the five required registrations, here.

Don’t be shy – speak to an HHS SBIR/STTR Program Manager! It is critical for success that applicants speak to a program manager before submitting! You should send the program manager a non-confidential abstract or executive summary of your research topic, including a description of your technology, which may include your specific aims. After you connect via email, you and the program manager may decide to set up a call to discuss your application in more detail. For questions about who to contact, please email sbir@od.nih.gov.

ASSIST vs. Downloadable Forms – You may submit your application using ASSIST or the Downloadable Forms method, starting on March 5, 2016. Please select the “Apply Online Using ASSIST” button, or the “Apply Using Downloadable Forms” button within the SBIR/STTR solicitation. View the ASSIST webinar materials here.

Be sure to use the Annotated SF424 SBIR/STTR Form Set in conjunction with the SF424 R&R SBIR/STTR Application Guide (FORMS-D) to guide you step-by-step through the application process. Applicants also find the Top 5 Most Common eRA Commons Errors and the SBIR Sample Application from NIAID helpful. All resources can be found on our Resources page.

Remember – The standard due dates occur on September 5, January 5, and April 5. The standard due dates apply to all SBIR/STTR solicitations that follow the Standard Due Dates, including the SBIR/STTR Omnibus solicitations and the Commercialization Readiness Pilot Program solicitations. You can find all solicitations here.

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1215 [post_author] => 3 [post_date] => 2014-07-31 13:35:56 [post_date_gmt] => 2014-07-31 13:35:56 [post_content] => The Center for Biotechnology at Stony Brook University has appointed Andreas Grill as the Center?s third BioEntrepreneur-In-Residence (B-EIR). Mr. Grill brings over twenty years of experience in the pharmaceutical industry to his appointment of B-EIR, having most recently served as the Executive Director of Forest Research Institute for Forest Laboratories, Inc. Mr. Grill will conduct due diligence to identify a technology or technologies around which he may build a company. As part of the B-EIR program, Mr. Grill will have access to the Center?s business and technology development support staff. Mr. Grill?s diverse and extensive experience in both business and research and development provide him with a unique perspective and advantage when it comes to launching a therapeutic-focused start-up. Read the full press release here. [post_title] => CFB Selects Third BioEntrepreneur-In-Residence [post_excerpt] => The Center for Biotechnology at Stony Brook University has appointed Andreas Grill as the Center?s third BioEntrepreneur-In-Residence (B-EIR). Mr. Grill brings over twenty years of experience... [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-selects-third-bioentrepreneur-in-residence [to_ping] => [pinged] => [post_modified] => 2015-01-28 16:58:26 [post_modified_gmt] => 2015-01-28 16:58:26 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1215 [menu_order] => 222 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2364 [post_author] => 4 [post_date] => 2016-08-11 17:51:20 [post_date_gmt] => 2016-08-11 17:51:20 [post_content] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). The Orphan Drug Designation program provides orphan status, and associated development incentives, to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Read more about the designation and company here. iCell [post_title] => iCell Gene Therapeutics Granted Orphan Drug Designation [post_excerpt] => iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => icell-gene-therapeutics-granted-orphan-drug-designation [to_ping] => [pinged] => [post_modified] => 2017-01-09 15:08:30 [post_modified_gmt] => 2017-01-09 15:08:30 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2364 [menu_order] => 168 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2224 [post_author] => 3 [post_date] => 2016-06-01 14:54:43 [post_date_gmt] => 2016-06-01 14:54:43 [post_content] => Join us at the Stony Brook University Incubator Company Showcase at CEWIT on June 2nd ! A joint effort by Stony Brook University's Centers of Excellence, Centers for Advanced Technology, Business Incubators and Development Centers,  the event showcases one of the nation's most comprehensive suite of economic development programs and the technological innovations and entrepreneurial advances of the University's burgeoning community of member companies. The Incubator Company Showcase will feature over 40 company exhibits and displays. Providing ample time for valuable networking and one-on-one conversations with our scope of biotechnology, energy and information technology companies. The event will also commemorate both the graduation and homegrown success of Codagenix, Inc. For more information and to register, visit http://goo.gl/5MPWqK. [post_title] => Stony Brook Incubator Company Showcase [post_excerpt] => Join us at the Stony Brook University Incubator Company Showcase at CEWIT on June 2nd featuring over 40 company exhibits and displays that highlight the technological innovations and entrepreneurial advances of the University's burgeoning community of member companies. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => stony-brook-incubator-company-showcase [to_ping] => [pinged] => [post_modified] => 2016-06-01 14:57:41 [post_modified_gmt] => 2016-06-01 14:57:41 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2224 [menu_order] => 179 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 259 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

CFB Selects Third BioEntrepreneur-In-Residence

More Information

iCell Gene Therapeutics Granted Orphan Drug Designation

More Information

Stony Brook Incubator Company Showcase

More Information